Drugmaker Novartis plans to spend $23 billion at 10 of its U.S. facilities, as the pharma industry grapples with Trump’s ...

Swiss pharmaceutical firm Novartis AG plans to invest $23 billion in the US over the next five years to ensure its key drugs ...

Swiss drugmaker Novartis said on Thursday it plans to spend $23 billion to build and expand 10 facilities in the U.S., as it ...

A Swiss drug giant has gotten the message from President Trump’s tariff threats. Novartis said Thursday it will spend $23 ...

The pharmaceutical firm will establish a research innovation hub in California, and manufacturing facilities in Florida, Texas, Indiana, and New Jersey.

European drugmaker Novartis (NVS), best known for blockbuster drugs like Entresto, Cosentyx, and Kesimpta, just announced a major U.S.

Swiss pharmaceutical giant Novartis announced it will spend $23 billion to build and expand 10 facilities in the United ...

Pluvicto, a prostate cancer drug, has gained expanded approval that triples the number of patients with metastatic disease ...

Novartis expects the new capacity will allow it to produce all of its key medicines “end to end” in the U.S., as the Trump ...

President Donald Trump's pressure to bring manufacturing jobs back to the U.S. appears to have influenced a pharmaceutical ...

North Carolina economic development officials terminated several incentives grants this week, including some tied to ...

Novartis (NVS) announced a planned $23B investment over five years in U.S.-based infrastructure, ensuring all key Novartis medicines for U.S.